RNA interference-guided targeting of hepatitis C virus replication with antisense locked nucleic acid-based oligonucleotides containing 8-oxo-dG modifications

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Mutso, Margit ^a,b   Nikonov, Andrei ^a,b   Pihlak, Arno ^b   Žusinaite, Eva ^a,b   Viru, Liane ^a,b   Selyutina, Anastasia ^a   Reintamm, Tõnu ^b,c   Kelve, Merike ^b,c   Saarma, Mart ^d   Karelson, Mati ^a,b   Merits, Andres ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b GeneCode Ltd   (Estonia)

^c TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANTISENSE OLIGONUCLEOTIDE; GENOMIC RNA; LOCKED NUCLEIC ACID; RIBONUCLEASE H; SMALL INTERFERING RNA; 8-OXO-7-HYDRODEOXYGUANOSINE; DEOXYGUANOSINE; GUIDE RNA; OLIGONUCLEOTIDE; VIRUS RNA;

ANTISENSE THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA DENATURATION; DNA MODIFICATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STABILITY; GENE TARGETING; GENETIC TRANSFECTION; HEPATITIS C VIRUS; HETERODUPLEX ANALYSIS; HUMAN; HUMAN CELL; MELTING POINT; NONHUMAN; PROTEIN CLEAVAGE; RESIDUE ANALYSIS; RNA CONFORMATION; RNA DEGRADATION; RNA INTERFERENCE; RNA SEQUENCE; THERMOSTABILITY; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BASE PAIRING; CHEMISTRY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; LIVER CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; RNA CLEAVAGE; RNA STABILITY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE; VIROLOGY;

HEPATITIS C VIRUS;

BASE PAIRING; CELL LINE, TUMOR; DEOXYGUANOSINE; GENOME, VIRAL; HEPACIVIRUS; HEPATOCYTES; HUMANS; MOLECULAR TARGETED THERAPY; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RNA CLEAVAGE; RNA INTERFERENCE; RNA STABILITY; RNA, GUIDE; RNA, SMALL INTERFERING; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 84935002053     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128686     Document Type: Article

References (79)

1. Kling J. Safety signal dampens reception for mipomersen antisense. Nat Biotechnol. 2010;28:295-297. doi: 10.1038/nbt0410-295 PMID: 20379153
2. Toulmé JJ. New candidates for true antisense. Nat Biotechnol. 2001;19:17-18. doi: 10.1038/83451 PMID: 11135542
3. Hausen P, Stein H. Ribonuclease H. An enzyme degrading the RNA moiety of DNA-RNA hybrids. Eur J Biochem FEBS. 1970;14:278-283. PMID: 5506170
4. Stein H, Hausen P. Enzyme from calf thymus degrading the RNA moiety of DNA-RNA Hybrids: effect on DNA-dependent RNA polymerase. Science. 1969;166:393-395. PMID: 5812039
5. Deleavey GF, Damha MJ. Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol. 2012;19:937-954. doi: 10.1016/j.chembiol.2012.07.011 PMID: 22921062
6. Furdon PJ, Dominski Z, Kole R. RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Res. 1989;17:9193-9204. PMID: 2555787
7. Rait VK, Shaw BR. Boranophosphates support the RNase H cleavage of polyribonucleotides. Antisense Nucleic Acid Drug Dev. 1999;9:53-60. PMID: 10192289
8. Sabatino D, Damha MJ. Oxepane nucleic acids: synthesis, characterization, and properties of oligonucleotides bearing a seven-membered carbohydrate ring. J Am Chem Soc. 2007;129:8259-8270. doi: 10.1021/ja071336c PMID: 17559214
9. Verbeure B, Lescrinier E, Wang J, Herdewijn P. RNase H mediated cleavage of RNA by cyclohexene nucleic acid (CeNA). Nucleic Acids Res. 2001;29:4941-4947. PMID: 11812823
10. Damha MJ, Wilds CJ, Noronha A, Brukner I, Borkow G, Arion D, et al. Hybrids of RNA and Arabinonucleic Acids (ANA and 2'F-ANA) Are Substrates of Ribonuclease H. J Am Chem Soc. 1998;120:12976-12977. doi: 10.1021/ja982325+
11. Heidenreich O, Gryaznov S, Nerenberg M. RNase H-independent antisense activity of oligonucleotide N3 → P5 β phosphoramidates. Nucleic Acids Res. 1997;25:776-780.
12. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta. 1999;1489:141-158. PMID: 10807004
13. Hanvey JC, Peffer NJ, Bisi JE, Thomson SA, Cadilla R, Josey JA, et al. Antisense and antigene properties of peptide nucleic acids. Science. 1992;258:1481-1485. PMID: 1279811
14. Renneberg D, Bouliong E, Reber U, Schümperli D, Leumann CJ. Antisense properties of tricyclo-DNA. Nucleic Acids Res. 2002;30:2751-2757. PMID: 12087157
15. Brown-Driver V, Eto T, Lesnik E, Anderson KP, Hanecak RC. Inhibition of translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 1999;9:145-154. PMID: 10355821
16. Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, et al. Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem. 1993;268:14514-14522. PMID: 8390996
17. Lok C-N, Viazovkina E, Min K-L, Nagy E, Wilds CJ, Damha MJ, et al. Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2'-deoxy-2'-fluoro-D-arabinose and 2'-deoxyribose nucleotides. Biochemistry (Mosc). 2002;41:3457-3467. PMID: 11876654
18. Grünweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 2003;31:3185-3193. PMID: 12799446
19. Kurreck J, Wyszko E, Gillen C, Erdmann VA. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 2002;30:1911-1918. PMID: 11972327
20. Wahlestedt C, Salmi P, Good L, Kela J, Johnsson T, Hökfelt T, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A. 2000;97:5633-5638. PMID: 10805816
21. Herdewijn P. Heterocyclic modifications of oligonucleotides and antisense technology. Antisense Nucleic Acid Drug Dev. 2000;10:297-310. doi: 10.1089/108729000421475 PMID: 10984123
22. Ueno Y, Kumagai I, Haginoya N, Matsuda A. Effects of 5-(N-aminohexyl) carbamoyl-2'-deoxyuridine on endonuclease stability and the ability of oligodeoxynucleotide to activate RNase H. Nucleic Acids Res. 1997;25:3777-3782. PMID: 9380497
23. Flanagan WM, Wolf JJ, Olson P, Grant D, Lin KY, Wagner RW, et al. A cytosine analog that confers enhanced potency to antisense oligonucleotides. Proc Natl Acad Sci U S A. 1999;96:3513-3518. PMID: 10097067
24. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem FEBS. 2003;270:1628-1644. PMID: 12694176
25. Zamaratski E, Pradeepkumar PI, Chattopadhyaya J. A critical survey of the structure-function of the antisense oligo/RNA heteroduplex as substrate for RNase H. J Biochem Biophys Methods. 2001;48:189-208. PMID: 11384757
26. Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368:1685-1694. doi: 10.1056/NEJMoa1209026 PMID: 23534542
27. Jin Q, Fleming AM, Ding Y, Burrows CJ, White HS. Structural Destabilization of DNA Duplexes Containing Single-Base Lesions Investigated by Nanopore Measurements. Biochemistry (Mosc). 2013;52:7870-7877. doi: 10.1021/bi4009825 PMID: 24128275
28. Ganguly M, Szulik MW, Donahue PS, Clancy K, Stone MP, Gold B. Thermodynamic signature of DNA damage: characterization of DNA with a 5-hydroxy-2'-deoxycytidine·2'-deoxyguanosine base pair. Biochemistry (Mosc). 2012;51:2018-2027. doi: 10.1021/bi3000269
29. Hamm ML, Parker AJ, Steele TWE, Carman JL, Parish CA. Oligonucleotide incorporation and base pair stability of 9-deaza-2'-deoxyguanosine, an analogue of 8-oxo-2'-deoxyguanosine. J Org Chem. 2010;75:5661-5669. doi: 10.1021/jo1010763 PMID: 20669985
30. Singh SK, Szulik MW, Ganguly M, Khutsishvili I, Stone MP, Marky LA, et al. Characterization of DNA with an 8-oxoguanine modification. Nucleic Acids Res. 2011;39:6789-6801. doi: 10.1093/nar/gkr275 PMID: 21572101
31. Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidationdamaged base 8-oxodG. Nature. 1991;349:431-434. doi: 10.1038/349431a0 PMID: 1992344
32. Suen W, Spiro TG, Sowers LC, Fresco JR. Identification by UV resonance Raman spectroscopy of an imino tautomer of 5-hydroxy-2'-deoxycytidine, a powerful base analog transition mutagen with a much higher unfavored tautomer frequency than that of the natural residue 2'-deoxycytidine. Proc Natl Acad Sci U S A. 1999;96:4500-4505. PMID: 10200291
33. Karelson M, Lomaka A. Quantum-chemical modeling of the tautomeric equilibria of modified anionic nucleic acid bases. Ark 2001 Iii 51-62. 2002;2:51-62.
34. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15:541-555. doi: 10.1038/nrg3763 PMID: 25022906
35. Murray S, Ittig D, Koller E, Berdeja A, Chappell A, Prakash TP, et al. TricycloDNA-modified oligo-20-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues-a comparative study of oligonucleotide length, design and chemistry. Nucleic Acids Res. 2012;40:6135-6143. doi: 10.1093/nar/gks273 PMID: 22467214
36. Hildebrandt-Eriksen ES, Aarup V, Persson R, Hansen HF, Munk ME, Ørum H. A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys. Nucleic Acid Ther. 2012;22:152-161. doi: 10.1089/nat.2011.0332 PMID: 22545703
37. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327:198-201. doi: 10.1126/science.1178178 PMID: 19965718
38. Simmonds P, Tuplin A, Evans DJ. Detection of genome-scale ordered RNA structure (GORS) in genomes of positive-stranded RNA viruses: Implications for virus evolution and host persistence. RNA N Y N. 2004;10:1337-1351. doi: 10.1261/rna.7640104 PMID: 15273323
39. Alt M, Renz R, Hofschneider PH, Paumgartner G, Caselmann WH. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatol Baltim Md. 1995;22:707-717.
40. Caldarelli SA, Mehiri M, Di Giorgio A, Martin A, Hantz O, Zoulim F, et al. A cyclic PNA-based compound targeting domain IV of HCV IRES RNA inhibits in vitro IRES-dependent translation. Bioorg Med Chem. 2005;13:5700-5709. doi: 10.1016/j.bmc.2005.06.008 PMID: 16061387
41. Hanecak R, Brown-Driver V, Fox MC, Azad RF, Furusako S, Nozaki C, et al. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J Virol. 1996;70:5203-5212. PMID: 8764029
42. Lima WF, Brown-Driver V, Fox M, Hanecak R, Bruice TW. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J Biol Chem. 1997;272:626-638. PMID: 8995306
43. McCaffrey AP, Meuse L, Karimi M, Contag CH, Kay MA. A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatol Baltim Md. 2003;38:503-508. doi: 10.1053/jhep. 2003.50330
44. Mizutani T, Kato N, Hirota M, Sugiyama K, Murakami A, Shimotohno K. Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells. Biochem Biophys Res Commun. 1995;212:906-911. doi: 10.1006/bbrc.1995.2055 PMID: 7626129
45. Nulf CJ, Corey D. Intracellular inhibition of hepatitis C virus (HCV) internal ribosomal entry site (IRES) - dependent translation by peptide nucleic acids (PNAs) and locked nucleic acids (LNAs). Nucleic Acids Res. 2004;32:3792-3798. doi: 10.1093/nar/gkh706 PMID: 15263060
46. Wakita T, Wands JR. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. J Biol Chem. 1994;269:14205-14210. PMID: 8188703
47. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-498. doi: 10.1038/35078107 PMID: 11373684
48. Lopp A, Reintamm T, Kuusksalu A, De Rosa S, Kelve M. A novel endoribonuclease from the marine sponge Tethya aurantium specific to 2', 5'-phosphodiester bonds. Biochimie. 2012;94:1635-1646. doi: 10.1016/j.biochi.2012.04.002 PMID: 22542997
49. You Y, Tataurov AV, Owczarzy R. Measuring thermodynamic details of DNA hybridization using fluorescence. Biopolymers. 2011;95:472-486. doi: 10.1002/bip. 21615 PMID: 21384337
50. Das PK, Merits A, Lulla A. Functional cross-talk between distant domains of chikungunya virus nonstructural protein 2 is decisive for its RNA-modulating activity. J Biol Chem. 2014;289:5635-5653. doi: 10.1074/jbc. M113.503433 PMID: 24407286
51. Nikonov A, Juronen E, Ustav M. Functional characterization of fingers subdomain-specific monoclonal antibodies inhibiting the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem. 2008;283:24089-24102. doi: 10.1074/jbc. M803422200 PMID: 18574240
52. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 2001;20:6877-6888. doi: 10.1093/emboj/20.23.6877 PMID: 11726523
53. Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci U S A. 2003;100:2014-2018. doi: 10.1073/pnas.252783999 PMID: 12566571
54. Wilson JA, Jayasena S, Khvorova A, Sabatinos S, Rodrigue-Gervais IG, Arya S, et al. RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci U S A. 2003;100:2783-2788. doi: 10.1073/pnas.252758799 PMID: 12594341
55. Frese M, Barth K, Kaul A, Lohmann V, Schwärzle V, Bartenschlager R. Hepatitis C virus RNA replication is resistant to tumour necrosis factor-alpha. J Gen Virol. 2003;84:1253-1259. PMID: 12692291
56. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell cultureadaptive mutations. J Virol. 2001;75:4614-4624. doi: 10.1128/JVI.75.10.4614-4624.2001 PMID: 11312331
57. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res. 2006;70:28-38. doi: 10.1016/j.antiviral.2005.12.003 PMID: 16448708
58. Burdick AD, Sciabola S, Mantena SR, Hollingshead BD, Stanton R, Warneke JA, et al. Sequence motifs associated with hepatotoxicity of locked nucleic acid-modified antisense oligonucleotides. Nucleic Acids Res. 2014;42:4882-4891. doi: 10.1093/nar/gku142 PMID: 24550163
59. Grünweller A, Hartmann RK. Locked nucleic acid oligonucleotides: the next generation of antisense agents? BioDrugs Clin Immunother Biopharm Gene Ther. 2007;21:235-243.
60. Nowotny M, Gaidamakov SA, Ghirlando R, Cerritelli SM, Crouch RJ, Yang W. Structure of Human RNase H1 Complexed with an RNA/DNA Hybrid: Insight into HIV Reverse Transcription. Mol Cell. 2007;28:264-276. doi: 10.1016/j.molcel.2007.08.015 PMID: 17964265
61. Min K-L, Viazovkina E, Galarneau A, Parniak MA, Damha MJ. Oligonucleotides comprised of alternating 2'-deoxy-2'-fluoro-beta-D-arabinonucleosides and D-2'-deoxyribonucleosides (2'F-ANA/DNA "altimers") induce efficient RNA cleavage mediated by RNase H. Bioorg Med Chem Lett. 2002;12:2651-2654. PMID: 12182880
62. Wu H, Lima WF, Crooke ST. Properties of Cloned and Expressed Human RNase H1. J Biol Chem. 1999;274:28270-28278. doi: 10.1074/jbc.274.40.28270 PMID: 10497183
63. Obad S, Dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet. 2011;43:371-378. doi: 10.1038/ng.786 PMID: 21423181
64. Jang YH, Goddard WA, Noyes KT, Sowers LC, Hwang S, Chung DS. First principles calculations of the tautomers and pK (a) values of 8-oxoguanine: implications for mutagenicity and repair. Chem Res Toxicol. 2002;15:1023-1035. PMID: 12184786
65. Watts JM, Dang KK, Gorelick RJ, Leonard CW, Bess JW, Swanstrom R, et al. Architecture and secondary structure of an entire HIV-1 RNA genome. Nature. 2009;460:711-716. doi: 10.1038/nature08237 PMID: 19661910
66. Pang PS, Elazar M, Pham EA, Glenn JS. Simplified RNA secondary structure mapping by automation of SHAPE data analysis. Nucleic Acids Res. 2011;39:e151. doi: 10.1093/nar/gkr773 PMID: 21965531
67. Romero-López C, Barroso-Deljesus A, García-Sacristán A, Briones C, Berzal-Herranz A. The folding of the hepatitis C virus internal ribosome entry site depends on the 3'-end of the viral genome. Nucleic Acids Res. 2012;40:11697-11713. doi: 10.1093/nar/gks927 PMID: 23066110
68. Tuplin A, Struthers M, Simmonds P, Evans DJ. A twist in the tail: SHAPE mapping of long-range interactions and structural rearrangements of RNA elements involved in HCV replication. Nucleic Acids Res. 2012;40:6908-6921. doi: 10.1093/nar/gks370 PMID: 22561372
69. Fiers W, Contreras R, Duerinck F, Haegeman G, Iserentant D, Merregaert J, et al. Complete nucleotide sequence of bacteriophage MS2 RNA: primary and secondary structure of the replicase gene. Nature. 1976;260:500-507. PMID: 1264203
70. Van Meerten D, Girard G, Van Duin J. Translational control by delayed RNA folding: identification of the kinetic trap. RNA N Y N. 2001;7:483-494. PMID: 11333027
71. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem FEBS. 2003;270:1628-1644. PMID: 12694176
72. Laxton C, Brady K, Moschos S, Turnpenny P, Rawal J, Pryde DC, et al. Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site. Antimicrob Agents Chemother. 2011;55:3105-3114. doi: 10.1128/AAC.00222-11 PMID: 21502629
73. Wilson JA, Richardson CD. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J Virol. 2005;79:7050-7058. doi: 10.1128/JVI. 79.11.7050-7058.2005 PMID: 15890944
74. Zhou J, Rossi JJ. Current progress in the development of RNAi-based therapeutics for HIV-1. Gene Ther. 2011;18:1134-1138. doi: 10.1038/gt.2011.149 PMID: 21956690
75. Van Der Ree MH, Van Der Meer AJ, De Bruijne J, Maan R, Van Vliet A, Welzel TM, et al. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antiviral Res. 2014;111:53-59. doi: 10.1016/j.antiviral.2014.08.015 PMID: 25218783
76. Ottosen S, Parsley TB, Yang L, Zeh K, Van Doorn L-J, Van Der Veer E, et al. In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122. Antimicrob Agents Chemother. 2015;59:599-608. doi: 10. 1128/AAC.04220-14 PMID: 25385103
77. Van Putten M, Young C, Van Den Berg S, Pronk A, Hulsker M, Karnaoukh TG, et al. Preclinical studies on intestinal administration of antisense oligonucleotides as a model for oral delivery for treatment of duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2014;3:e211. doi: 10.1038/mtna.2014.62 PMID: 25405468
78. Tillman LG, Geary RS, Hardee GE. Oral delivery of antisense oligonucleotides in man. J Pharm Sci. 2008;97:225-236. doi: 10.1002/jps.21084 PMID: 17721945
79. Hair P, Cameron F, McKeage K. Mipomersen sodium: first global approval. Drugs. 2013;73:487-493. doi: 10.1007/s40265-013-0042-2 PMID: 23564617